Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics

Aflibercept

(2013) K. K. Ciombor et al.   CLINICAL CANCER RESEARCH

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

(2012) Nicholas Papadopoulos et al.   ANGIOGENESIS

Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation

(2012) Darius Ghaderi et al.   Biotechnology & Genetic Engineering Reviews

Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs

(2012) J. A. Dumont et al.   BLOOD

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

(2012) J. S. Powell et al.   BLOOD

Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours

(2012) G Freyer et al.   BRITISH JOURNAL OF CANCER

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours

(2012) I Diaz-Padilla et al.   BRITISH JOURNAL OF CANCER

Cross-presentation of IgG-containing immune complexes

(2012) Kristi Baker et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors

(2012) N. Isambert et al.   CLINICAL CANCER RESEARCH

Dead on Arrival: Understanding the Failure of CTLA4-Immunoglobulin Therapy in Inflammatory Bowel Disease

(2012) Lloyd Mayer et al.   GASTROENTEROLOGY

Abatacept for Crohn's Disease and Ulcerative Colitis

(2012) William J. Sandborn et al.   GASTROENTEROLOGY

Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)

(2012) T. C. Abshire et al.   HAEMOPHILIA

Soluble Monomeric IgG1 Fc

(2012) Tianlei Ying et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Which are the antibodies to watch in 2012?

(2012) Janice M. Reichert   mAbs

The discovery and development of belimumab: the anti-BLyS–lupus connection

(2012) William Stohl et al.   NATURE BIOTECHNOLOGY

Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions

(2012) J. T. Sockolosky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial

(2012) Ellen M Ginzler et al.   ARTHRITIS RESEARCH & THERAPY

Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development?

(2012) William Stohl   Current Rheumatology Reports

Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial

(2011) R. F. van Vollenhoven et al.   ARTHRITIS AND RHEUMATISM

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase II, randomized, placebo-controlled, dose-finding trial

(2011) M. C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients

(2011) A. D. Shapiro et al.   BLOOD

Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences

(2011) W. Wang et al.   DRUG METABOLISM AND DISPOSITION

Neonatal Fc Receptor Blockade by Fc Engineering Ameliorates Arthritis in a Murine Model

(2011) D. A. Patel et al.   JOURNAL OF IMMUNOLOGY

Pulmonary Administration of Interferon Beta-1a-Fc Fusion Protein in Non-Human Primates Using an Immunoglobulin Transport Pathway

(2011) Sebastien Vallee et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

A Neonatal Fc Receptor-Targeted Mucosal Vaccine Strategy Effectively Induces HIV-1 Antigen-Specific Immunity to Genital Infection

(2011) L. Lu et al.   JOURNAL OF VIROLOGY

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

(2011) Tihamer Orban et al.   LANCET

Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer

(2011) Robert L Coleman et al.   LANCET ONCOLOGY

Biosimilar, biobetter and next generation therapeutic antibodies

(2011) Alain Beck   mAbs

Neonatal Fc receptor for IgG (FcRn) expressed in the gastric epithelium regulates bacterial infection in mice

(2011) Y Ben Suleiman et al.   Mucosal Immunology

Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway

(2011) Robert M. Anthony et al.   NATURE

What's fueling the biotech engine—2010 to 2011

(2011) Saurabh Aggarwal   NATURE BIOTECHNOLOGY

Efficient mucosal vaccination mediated by the neonatal Fc receptor

(2011) Lilin Ye et al.   NATURE BIOTECHNOLOGY

Advances in the assessment and control of the effector functions of therapeutic antibodies

(2011) Xu-Rong Jiang et al.   NATURE REVIEWS DRUG DISCOVERY

Structure of FcRY, an avian immunoglobulin receptor related to mammalian mannose receptors, and its complex with IgY

(2011) Y. He et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intracellular neutralization of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-mediated IgG transport

(2011) Y. Bai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells

(2011) K. Baker et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection

(2011) Z. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibody drug conjugates — Trojan horses in the war on cancer

(2011) U. Iyer et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

(2010) J. T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial

(2010) Philip Mease et al.   ARTHRITIS AND RHEUMATISM

Prolonged activity of factor IX as a monomeric Fc fusion protein

(2010) R. T. Peters et al.   BLOOD

Post-translational modifications of protein biopharmaceuticals

(2010) Gary Walsh   DRUG DISCOVERY TODAY

Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor-  Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus Monkeys

(2010) R. Deng et al.   DRUG METABOLISM AND DISPOSITION

The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis

(2010) Janet L. Roberts et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Five-Year Safety and Efficacy of Belatacept in Renal Transplantation

(2010) F. Vincenti et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Antibodies to watch in 2010

(2010) Janice M. Reichert   mAbs

Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization

(2010) Tomoyuki Igawa et al.   NATURE BIOTECHNOLOGY

Enhanced antibody half-life improves in vivo activity

(2010) Jonathan Zalevsky et al.   NATURE BIOTECHNOLOGY

Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins

(2010) Darius Ghaderi et al.   NATURE BIOTECHNOLOGY

Development trends for human monoclonal antibody therapeutics

(2010) Aaron L. Nelson et al.   NATURE REVIEWS DRUG DISCOVERY

Rilonacept-CAPS and Beyond

(2009) Neil Stahl et al.   Annals of the New York Academy of Sciences

Can we prevent immunogenicity of human protein drugs?

(2009) D W Scott et al.   ANNALS OF THE RHEUMATIC DISEASES

Fc-Based Cytokines

(2009) Jalal A Jazayeri et al.   BIODRUGS

CD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells

(2009) M. S. Hayden-Ledbetter et al.   CLINICAL CANCER RESEARCH

Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics

(2009) Anne S. De Groot et al.   CLINICAL IMMUNOLOGY

Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology

(2009) Chichi Huang   CURRENT OPINION IN BIOTECHNOLOGY

Potent antibody drug conjugates for cancer therapy

(2009) Peter D Senter   CURRENT OPINION IN CHEMICAL BIOLOGY

Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors

(2009) Quincy Siu-Chung Chu   EXPERT OPINION ON BIOLOGICAL THERAPY

Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis

(2009) C Bracewell et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

An FcRn-Dependent Role for Anti-flagellin Immunoglobulin G in Pathogenesis of Colitis in Mice

(2009) Kanna Kobayashi et al.   GASTROENTEROLOGY

N-Glycan Moieties in Neonatal Fc Receptor Determine Steady-state Membrane Distribution and Directional Transport of IgG

(2009) Timothy T. Kuo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity

(2009) Salit Tzaban et al.   JOURNAL OF CELL BIOLOGY

Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates

(2009) Y. A. Yeung et al.   JOURNAL OF IMMUNOLOGY

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

(2009) C Pena-Rossi et al.   LUPUS

Structural characterization of a human Fc fragment engineered for extended serum half-life

(2009) Vaheh Oganesyan et al.   MOLECULAR IMMUNOLOGY

IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab

(2009) Charlotte Magdelaine-Beuzelin et al.   Pharmacogenetics and Genomics

Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice

(2009) Héctor Pérez Montoyo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn

(2009) Kristi Baker et al.   Seminars in Immunopathology

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

(2008) M K de Vries et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies

(2008) Hal M. Hoffman et al.   ARTHRITIS AND RHEUMATISM

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP

(2008) J. B. Bussel et al.   BLOOD

Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"

(2008) A. S. De Groot et al.   BLOOD

Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: A phase I, open-label, dose-escalation clinical study

(2008) Daniel J. Burge et al.   CLINICAL THERAPEUTICS

Fully human antibodies from transgenic mouse and phage display platforms

(2008) Nils Lonberg   CURRENT OPINION IN IMMUNOLOGY

Editorial [Hot Topic: Therapeutic Antibodies and Derivatives: From the Bench to the Clinic(Guest Editor: Alain Beck)]

(2008) A. Beck et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Monoclonal Antibodies as Innovative Therapeutics

(2008) Janice Reichert   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

β2-Microglobulin Deficient Mice Catabolize IgG More Rapidly Than FcRn-α-Chain Deficient Mice

(2008) Jonghan Kim et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: Potential implications for disease

(2008) V. Padler-Karavani et al.   GLYCOBIOLOGY

The Chicken Yolk Sac IgY Receptor, a Mammalian Mannose Receptor Family Member, Transcytoses IgY across Polarized Epithelial Cells

(2008) Devin B. Tesar et al.   MOLECULAR BIOLOGY OF THE CELL

CTLA4Ig treatment in patients with multiple sclerosis: An open-label, phase 1 clinical trial

(2008) V. Viglietta et al.   NEUROLOGY

Dependence of antibody-mediated presentation of antigen on FcRn

(2008) S.-W. Qiao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of a receptor required for the anti-inflammatory activity of IVIG

(2008) R. M. Anthony et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis

(2007) A. Ephrem et al.   BLOOD